Article section

Article title
Contributor
Abstract
About article
DOI
Citation style
Copyright
Open access
References
Review Article

Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity

Authors

Abstract

Orphan drug development for rare diseases presents unique challenges that require targeted scientific, economic, and policy-based responses. With over 300 million individuals globally affected by rare diseases, the need for effective therapies is urgent. However, development is hindered by limited biological understanding, small patient populations, and difficulties in clinical trial recruitment. High research and development costs and inconsistent market incentives further discourage investment, especially in low- and middle-income countries (LMICs). Ethical concerns around access and affordability deepen disparities. To address these issues, legislative measures such as the U.S. Orphan Drug Act and similar policies in the EU and Japan offer benefits like market exclusivity and expedited regulatory review. Advances in genomic sequencing, artificial intelligence, and real-world data are enhancing diagnostics and drug discovery. Collaborative research models, adaptive trial designs, and decentralized clinical trials improve feasibility and inclusivity. Equity-driven frameworks such as tiered pricing and support for local manufacturing are critical to expanding access in LMICs.This article examines the interconnected challenges of orphan drug development and outlines evidence-based strategies to improve therapeutic innovation and global access. A coordinated, multisectoral effort is essential to ensure that the benefits of precision medicine and translational research extend beyond high-income countries and contribute to global health equity.

Keywords:

Drug Development Low- And Middle-Income Countries (LMICS) Orphan Drugs Precision Medicine Rare Diseases

Article information

Journal

Journal of Life Science and Public Health

Volume (Issue)

1(1), (2025)

Pages

1-9

Published

20-06-2025

How to Cite

Lawal, O. P., Orobator, E. T., Dorcas, S. I., Ezeamii, V. C., Foster-Pagaebi, E., & Attahiru, M. (2025). Orphan Drug Development for Rare Diseases: Therapeutic Challenges, Translational Strategies, and Global Health Equity. Journal of Life Science and Public Health, 1(1), 1-9. https://doi.org/10.69739/jlsph.v1i1.538

References

Aartsma-Rus, A., Dooms, M., & Le Cam, Y. (2021). Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Frontiers in Pharmacology, 12, 744532. https://doi.org/10.3389/fphar.2021.744532

Abubakar, I., Dalglish, S. L., Angell, B., Sanuade, O., Abimbola, S., Adamu, A. L., Adetifa, I. M. O., Colbourn, T., Ogunlesi, A. O., Onwujekwe, O., Owoaje, E. T., Okeke, I. N., Adeyemo, A., Aliyu, G., Aliyu, M. H., Aliyu, S. H., Ameh, E. A., Archibong, B., Ezeh, A., … Zanna, F. H. (2022). The Lancet Nigeria Commission: Investing in health and the future of the nation. Lancet, 399(10330), 1155–1200. https://doi.org/10.1016/S0140-6736(21)02488-0

Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023). Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. International Journal of Environmental Research and Public Health, 20(6), 4732. https://doi.org/10.3390/ijerph20064732

Al-kfairy, M., Mustafa, D., Kshetri, N., Insiew, M., & Alfandi, O. (2024). Ethical Challenges and Solutions of Generative AI: An Interdisciplinary Perspective. Informatics, 11(3), 58. https://doi.org/10.3390/informatics11030058

Althobaiti, H., Seoane-Vazquez, E., Brown, L. M., Fleming, M. L., & Rodriguez-Monguio, R. (2023). Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare, 11(4), 558. https://doi.org/10.3390/healthcare11040558

Austin, C. P., Cutillo, C. M., Lau, L. P. L., Jonker, A. H., Rath, A., Julkowska, D., Thomson, D., Terry, S. F., de Montleau, B., Ardigò, D., Hivert, V., Boycott, K. M., Baynam, G., Kaufmann, P., Taruscio, D., Lochmüller, H., Suematsu, M., Incerti, C., Draghia-Akli, R., … International Rare Diseases Research Consortium (IRDiRC). (2018). Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Clinical and Translational Science, 11(1), 21–27. https://doi.org/10.1111/cts.12500

Ayati, N., Afzali, M., Hasanzad, M., Kebriaeezadeh, A., Rajabzadeh, A., & Nikfar, S. (2021). Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country. Iranian Journal of Pharmaceutical Research: IJPR, 20(4), 92–106. https://doi.org/10.22037/ijpr.2021.114899.15091

Ayomide, I. T., Promise, L. O., Christopher, A. A., Okikiola, P. P., Esther, A. D., Favour, A. C., Agbo, O. S., Sandra, O.-A., Chiagozie, O. J., Precious, A. C., & Ugonna, U. K. (2024). The Impact of Antimicrobial Resistance on Co-INFECTIONS: Management Strategies for HIV, TB and Malaria. International Journal of Pathogen Research, 13(6), 117–128. https://doi.org/10.9734/ijpr/2024/v13i6326

Boulanger, V., Schlemmer, M., Rossov, S., Seebald, A., & Gavin, P. (2020). Establishing Patient Registries for Rare Diseases: Rationale and Challenges. Pharmaceutical Medicine, 34(3), 185–190. https://doi.org/10.1007/s40290-020-00332-1

Chung, C. C. Y., Hong Kong Genome Project, Chu, A. T. W., & Chung, B. H. Y. (2022). Rare disease emerging as a global public health priority. Frontiers in Public Health, 10, 1028545. https://doi.org/10.3389/fpubh.2022.1028545

Costa, E., Moja, L., Wirtz, V. J., van den Ham, H. A., Huttner, B., Magrini, N., & Leufkens, H. G. (2024). Uptake of orphan drugs in the WHO essential medicines lists. Bulletin of the World Health Organization, 102(1), 22–31. https://doi.org/10.2471/BLT.23.289731

Crisafulli, S., Boccanegra, B., Vitturi, G., Trifirò, G., & De Luca, A. (2023). Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical-Experimental, and Real-World Evidence. Brain Sciences, 13(10), 1446. https://doi.org/10.3390/brainsci13101446

Elechi, K. W., Igboaka, C. D., Tiamiyu, B. B., Ugbor, M.-J. E., Arthur, C., Ezeh, O. M., Faderin, E. A., Olowookere, A., Lawal, O. P., Elechi, K. W., Igboaka, C. D., Tiamiyu, B. B., Ugbor, M.-J. E., Arthur, C., Ezeh, O. M., Faderin, E. A., Olowookere, A., & Lawal, O. P. (2025). Phytochemical Screening of Ficus globosa Latex (Moraceae) as a Source of Novel Antimicrobial Compounds. Path of Science, 11(3), Article 3. https://doi.org/10.22178/pos.115-28

FDA orphan products clinical trial grants: Assessment of outcomes and impact on rare disease product development—PubMed. (n.d.). Retrieved April 27, 2025, from https://pubmed.ncbi.nlm.nih.gov/32883327

Fuhrer, M., Zampoli, M., & Abriel, H. (2024). Diagnosing cystic fibrosis in low- and middle-income countries: Challenges and strategies. Orphanet Journal of Rare Diseases, 19(1), 482. https://doi.org/10.1186/s13023-024-03506-1

Gabay, M. (2019). The Orphan Drug Act: An Appropriate Approval Pathway for Treatments of Rare Diseases? Hospital Pharmacy, 54(5), 283–284. https://doi.org/10.1177/0018578719867665

Gilardino, R. E., Valanzasca, P., & Rifkin, S. B. (2022). Has Latin America achieved universal health coverage yet? Lessons from four countries. Archives of Public Health, 80(1), 38. https://doi.org/10.1186/s13690-022-00793-7

Iskandar, K., Murugaiyan, J., Hammoudi Halat, D., Hage, S. E., Chibabhai, V., Adukkadukkam, S., Roques, C., Molinier, L., Salameh, P., & Van Dongen, M. (2022). Antibiotic Discovery and Resistance: The Chase and the Race. Antibiotics (Basel, Switzerland), 11(2), 182. https://doi.org/10.3390/antibiotics11020182

Iyer, K. A., Tenchov, R., Sasso, J. M., Ralhan, K., Jotshi, J., Polshakov, D., Maind, A., & Zhou, Q. A. (2025). Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research. Biochemistry, 64(8), 1698–1719. https://doi.org/10.1021/acs.biochem.4c00722

Junaid, S. B., Imam, A. A., Balogun, A. O., De Silva, L. C., Surakat, Y. A., Kumar, G., Abdulkarim, M., Shuaibu, A. N., Garba, A., Sahalu, Y., Mohammed, A., Mohammed, T. Y., Abdulkadir, B. A., Abba, A. A., Kakumi, N. A. I., & Mahamad, S. (2022). Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. Healthcare, 10(10), 1940. https://doi.org/10.3390/healthcare10101940

Ko, J. M. (2024). Advancing orphan drug development for rare diseases. Clinical and Experimental Pediatrics, 67(7), 356–357. https://doi.org/10.3345/cep.2023.01109

Krishnaraj, P., & Rajasimha, H. K. (2024). Cross-border rare disease advocacy: Preethi Krishnaraj interviews Harsha Rajasimha. Disease Models & Mechanisms, 17(6), dmm050672. https://doi.org/10.1242/dmm.050672

Lawal, O., Elechi, K., Adekunle, F., Farinde, O., Kolapo, T., Igbokwe, C., Elechi, U., Victoria, & Chikezie, O. (2025). A Review on Artificial Intelligence and Point-of-Care Diagnostics to Combat Antimicrobial Resistance in Resource-Limited Healthcare Settings like Nigeria: Review Article. Journal of Pharma Insights and Research, 3(2), Article 2. https://doi.org/10.69613/reeh4906

Mahajan, R. (2019). Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever. International Journal of Applied & Basic Medical Research, 9(3), 127–128. https://doi.org/10.4103/ijabmr.IJABMR_190_19

Ming, D. K., Sangkaew, S., Chanh, H. Q., Nhat, P. T. H., Yacoub, S., Georgiou, P., & Holmes, A. H. (2020). Continuous physiological monitoring using wearable technology to inform individual management of infectious diseases, public health and outbreak responses. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 96, 648–654. https://doi.org/10.1016/j.ijid.2020.05.086

Neil, E. E., & Bisaccia, E. K. (2019). Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. The Journal of Pediatric Pharmacology and Therapeutics: JPPT: The Official Journal of PPAG, 24(3), 194–203. https://doi.org/10.5863/1551-6776-24.3.194

Ngoumou, R.-D., & Feudjio, Y. B. D. (2024). The management of rare disease patients from a grassroot perspective: The role of patients’ organizations in the global recognition of rare diseases in Cameroon. The Pan African Medical Journal, 47, 64. https://doi.org/10.11604/pamj.2024.47.64.38226

Okafor, C. E., Egwuatu, E. C., Owosagba, V. A., Njei, T., Adeyemi, B. I., Onuche, P. U. O., Adams, A., Ugwuja, C. B., Chibueze, E. S., & Lawal, O. P. (2025). From Bench to Bedside: Medicinal Chemistry Strategies in the Development of Kinase Inhibitors for Cancer Therapy. Journal of Cancer and Tumor International, 15(2), 79–96. https://doi.org/10.9734/jcti/2025/v15i2294

Olliaro, P., & Torreele, E. (2024). The priority review voucher: A misconceived quid pro quo. BMJ Global Health, 9(12), e015933. https://doi.org/10.1136/bmjgh-2024-015933

Patterson, A. M., O’Boyle, M., VanNoy, G. E., & Dies, K. A. (2023). Emerging roles and opportunities for rare disease patient advocacy groups. Therapeutic Advances in Rare Disease, 4, 26330040231164425. https://doi.org/10.1177/26330040231164425

Renfro, L. A., & Sargent, D. J. (2017). Statistical controversies in clinical research: Basket trials, umbrella trials, and other master protocols: a review and examples. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28(1), 34–43. https://doi.org/10.1093/annonc/mdw413

Risse, J., Krzemien, M., Schnalke, J., & Heinemann, T. (2024). Towards ethical drug pricing: The European Orphan Genomic Therapies Fund. Gene Therapy, 31(7–8), 353–357. https://doi.org/10.1038/s41434-024-00452-2

Rodrigues, N. J. P. (2023). Public-Private Partnerships Model Applied to Hospitals-A Critical Review. Healthcare, 11(12), 1723. https://doi.org/10.3390/healthcare11121723

Shafie, A. A., Supian, A., Ahmad Hassali, M. A., Ngu, L.-H., Thong, M.-K., Ayob, H., & Chaiyakunapruk, N. (2020). Rare disease in Malaysia: Challenges and solutions. PloS One, 15(4), e0230850. https://doi.org/10.1371/journal.pone.0230850

Vinekar, A., & Jayadev, C. (2022). Balancing patient need with public policy in rare diseases—A legal perspective. Indian Journal of Ophthalmology, 70(7), 2584. https://doi.org/10.4103/ijo.IJO_905_22

Visan, A. I., & Negut, I. (2024). Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life, 14(2), 233. https://doi.org/10.3390/life14020233

Yoo, H.-W. (2024). Development of orphan drugs for rare diseases. Clinical and Experimental Pediatrics, 67(7), 315–327. https://doi.org/10.3345/cep.2023.00535

Downloads

Views

98

Downloads

47